Targeting atrial fibrillation promoting atrial structural remodeling: is this a viable strategy in patients with heart failure?
作者信息
Li Na, Dobrev Dobromir
机构信息
Cardiovascular Research Institute, Baylor College of Medicine, Houston, TX, USA.
Department of Medicine (Section of Cardiovascular Research), Baylor College of Medicine, Houston, TX, USA.
出版信息
Naunyn Schmiedebergs Arch Pharmacol. 2018 Mar;391(3):231-233. doi: 10.1007/s00210-018-1463-y. Epub 2018 Jan 11.
Abstract
摘要
相似文献
1
Targeting atrial fibrillation promoting atrial structural remodeling: is this a viable strategy in patients with heart failure?针对促进心房结构重塑的心房颤动：这对心力衰竭患者而言是一种可行的策略吗？
Naunyn Schmiedebergs Arch Pharmacol. 2018 Mar;391(3):231-233. doi: 10.1007/s00210-018-1463-y. Epub 2018 Jan 11.
2
Atrial Ca/calmodulin-dependent protein kinase II: A druggable master switch of atrial fibrillation-associated atrial remodeling?心房钙/钙调蛋白依赖性蛋白激酶II：房颤相关心房重塑的一个可药物作用的主控开关？
Heart Rhythm. 2019 Jul;16(7):1089-1090. doi: 10.1016/j.hrthm.2019.02.002. Epub 2019 Feb 5.
3
Atrial fibrillation and heart failure-associated remodeling of two-pore-domain potassium (K) channels in murine disease models: focus on TASK-1.心房颤动和心力衰竭相关的双孔钾 (K) 通道在小鼠疾病模型中的重构：聚焦 TASK-1。
Basic Res Cardiol. 2018 Jun 7;113(4):27. doi: 10.1007/s00395-018-0687-9.
4
5
Three-dimensional Integrated Functional, Structural, and Computational Mapping to Define the Structural "Fingerprints" of Heart-Specific Atrial Fibrillation Drivers in Human Heart Ex Vivo.三维综合功能、结构和计算图谱，以确定人心外植体中心脏特异性心房颤动驱动因素的结构“指纹”。
J Am Heart Assoc. 2017 Aug 22;6(8):e005922. doi: 10.1161/JAHA.117.005922.
6
Increased expression of NF-AT3 and NF-AT4 in the atria correlates with procollagen I carboxyl terminal peptide and TGF-β1 levels in serum of patients with atrial fibrillation.心房中NF-AT3和NF-AT4表达增加与心房颤动患者血清中I型前胶原羧基末端肽及转化生长因子-β1水平相关。
BMC Cardiovasc Disord. 2014 Nov 25;14:167. doi: 10.1186/1471-2261-14-167.
7
Novel Upstream Approaches to Prevent Atrial Fibrillation Perpetuation.预防心房颤动持续存在的新型上游方法。
Heart Fail Clin. 2016 Apr;12(2):309-22. doi: 10.1016/j.hfc.2015.08.024.
8
Atrial fibrillation: a progressive atrial myopathy or a distinct disease?心房颤动：进行性心房肌病还是一种独特的疾病？
Int J Cardiol. 2014 Feb 1;171(2):126-33. doi: 10.1016/j.ijcard.2013.12.009. Epub 2013 Dec 18.
9
Reply to letter to the editor: "A potential and lionhearted soldier for atrial fibrillation accompanied with heart failure: Renal denervation".致编辑的信的回复：“心房颤动伴心力衰竭的一位潜在且勇敢的战士：肾去神经支配”
Int J Cardiol. 2017 Sep 15;243:282. doi: 10.1016/j.ijcard.2017.05.035.
10
Atrial remodelling in atrial fibrillation: CaMKII as a nodal proarrhythmic signal.心房颤动中的心房重塑：CaMKII作为一个关键的促心律失常信号。
Cardiovasc Res. 2016 Apr 1;109(4):542-57. doi: 10.1093/cvr/cvw002. Epub 2016 Jan 13.
引用本文的文献
1
Serum interleukin-6, tumour necrosis factor-a, D-dimer after recombinant human brain natriuretic peptide combined with levosimendan in patients with heart failure.重组人脑利钠肽联合左西孟旦治疗心力衰竭患者后血清白细胞介素-6、肿瘤坏死因子-α、D-二聚体水平
J Med Biochem. 2025 Aug 21;44(5):1100-1109. doi: 10.5937/jomb0-56202.
2
Resveratrol: an effective pharmacological agent to prevent inflammation-induced atrial fibrillation?白藜芦醇：一种预防炎症诱导的心房颤动的有效药理剂？
Naunyn Schmiedebergs Arch Pharmacol. 2018 Nov;391(11):1163-1167. doi: 10.1007/s00210-018-1566-5. Epub 2018 Sep 20.
本文引用的文献
1
DL-3-n-Butylphthalide reduces atrial fibrillation susceptibility by inhibiting atrial structural remodeling in rats with heart failure.DL-3-正丁基苯酞通过抑制心力衰竭大鼠心房结构重塑降低心房颤动易感性。
Naunyn Schmiedebergs Arch Pharmacol. 2018 Mar;391(3):323-334. doi: 10.1007/s00210-017-1457-1. Epub 2017 Dec 30.
2
Atrial Fibrillation in Heart Failure: a Therapeutic Challenge of Our Times.心力衰竭中的心房颤动：当今时代的治疗挑战
Korean Circ J. 2017 Sep;47(5):644-662. doi: 10.4070/kcj.2017.0040. Epub 2017 Aug 22.
3
Renin-angiotensin blockade in heart failure with preserved ejection fraction: a systematic review and meta-analysis.肾素-血管紧张素阻断剂在射血分数保留型心力衰竭中的应用：系统评价和荟萃分析。
ESC Heart Fail. 2017 Nov;4(4):402-408. doi: 10.1002/ehf2.12204. Epub 2017 Sep 4.
4
Controversies About Atrial Fibrillation Mechanisms: Aiming for Order in Chaos and Whether it Matters.心房颤动机制的争议：力求在混乱中找到秩序以及这是否重要。
Circ Res. 2017 Apr 28;120(9):1396-1398. doi: 10.1161/CIRCRESAHA.116.310489.
5
Atrial fibrillation in heart failure with preserved ejection fraction: Insights into mechanisms and therapeutics.射血分数保留的心力衰竭中的心房颤动：对发病机制和治疗的深入了解。
Pharmacol Ther. 2017 Aug;176:32-39. doi: 10.1016/j.pharmthera.2016.10.019. Epub 2016 Oct 20.
6
Electrophysiological and molecular mechanisms of paroxysmal atrial fibrillation.阵发性心房颤动的电生理和分子机制。
Nat Rev Cardiol. 2016 Oct;13(10):575-90. doi: 10.1038/nrcardio.2016.118. Epub 2016 Aug 4.
7
Novel Upstream Approaches to Prevent Atrial Fibrillation Perpetuation.预防心房颤动持续存在的新型上游方法。
Heart Fail Clin. 2016 Apr;12(2):309-22. doi: 10.1016/j.hfc.2015.08.024.
8
DL-3-n-butylphthalide delays the onset and progression of diabetic cataract by inhibiting oxidative stress in rat diabetic model.在大鼠糖尿病模型中，丁苯酞通过抑制氧化应激延缓糖尿病性白内障的发生和发展。
Sci Rep. 2016 Jan 13;6:19396. doi: 10.1038/srep19396.
9
The value of basic research insights into atrial fibrillation mechanisms as a guide to therapeutic innovation: a critical analysis.对心房颤动机制的基础研究见解作为治疗创新指南的价值：批判性分析
Cardiovasc Res. 2016 Apr 1;109(4):467-79. doi: 10.1093/cvr/cvv275. Epub 2015 Dec 23.
10
Atrial fibrillation therapy now and in the future: drugs, biologicals, and ablation.心房颤动治疗的现在和未来：药物、生物制剂和消融。
Circ Res. 2014 Apr 25;114(9):1532-46. doi: 10.1161/CIRCRESAHA.114.302362.
Zotero 插件